Skip to Content

Join the 'Hodgkin's Lymphoma' group to help and get support from people like you.

Hodgkin's Lymphoma News

Related terms: Cancer, Hodgkin's Lymphoma, Hodgkin's Disease, Lymphoma, Hodgkin's

FDA Approves Merck’s Keytruda (pembrolizumab) for Classical Hodgkin Lymphoma (cHL)

Posted 15 Mar 2017 by Drugs.com

KENILWORTH, N.J. March 14, 2017 --(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after three or more prior lines of therapy. Under the FDA’s accelerated approval regulations, this indication is approved based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. In refractory or relapsed cHL, Keytruda is approved for use in adult patients at a fixed dose of 200 mg and in pediatric patients at a dose of 2 mg/kg (up to a maximum of 200 ... Read more

Related support groups: Lymphoma, Keytruda, Hodgkin's Lymphoma, Pembrolizumab

Hodgkin Lymphoma Survivors Face Risk of Second Cancer: Study

Posted 13 Mar 2017 by Drugs.com

MONDAY, March 13, 2017 – The risk of developing a second type of cancer may be high among Hodgkin lymphoma survivors, especially those with a family history of cancer. That's the finding of a new European study in which researchers examined data from more than 9,500 Hodgkin lymphoma patients. Hodgkin lymphoma, once known as Hodgkin's disease, is a cancer that starts in the white blood cells called lymphocytes. Lymphocytes are part of the immune system, according to the American Cancer Society. "The vast majority of patients with Hodgkin lymphoma are cured with a combination of chemotherapy and radiotherapy," said study author Amit Sud, a clinical research fellow at the Institute of Cancer Research in London. "Our research has shown that these patients are at substantially increased risk of a second cancer later in life – and particularly if they have a family history of cancer," Sud ... Read more

Related support groups: Blood Disorders, Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Hodgkin's Lymphoma

Health Highlights: March 13, 2017

Posted 13 Mar 2017 by Drugs.com

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Consumer Advocates Pan Trump's Choice for FDA Head A former top official in the U.S. Food and Drug Administration during the administration of President George W. Bush is President Donald Trump's choice to lead the agency. The nomination of Scott Gottlieb, 44, was welcomed by drug industry executives but criticized by consumer advocates, who said he is too deeply tied to pharmaceutical companies, The New York Times reported. Gottlieb is a partner at a venture capital fund with extensive links to the medicine and biotech industries. "He is basically entangled in an unprecedented web of ties to big pharma," Dr. Michael Carome, director of the health research group at the consumer organization Public Citizen, told The Times. "He is someone who has been an industry shill and has spent ... Read more

Related support groups: Poisoning, Addison's Disease, Hodgkin's Lymphoma, Toxic Reactions Incl Drug and Substance Abuse, Meningitis - Listeriosis

DNA Sequencing May Lead to Personalized Cancer Treatment

Posted 9 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 9, 2016 – DNA sequencing may help personalize treatment for people with lymphoma, a new study suggests. By analyzing small bits of DNA in the blood, researchers at Stanford University School of Medicine said they could determine the cancer's subtype. They said they could also identify mutations that might make treatment less effective or worsen a patient's prognosis. The study authors said their findings add to growing evidence that noninvasive, blood-based biopsies may help detect cancer earlier by tracking its evolution. They said this test may also significantly change how the disease is treated. "Now we can identify the subtype of the tumor, watch how it changes over time and begin to tailor our chemotherapy choices based on the presence or absence of specific mutations," said study co-senior author Dr. Ash Alizadeh, an assistant professor of medicine/oncology. ... Read more

Related support groups: Cancer, Lymphoma, Non-Hodgkin's Lymphoma, Cutaneous T-cell Lymphoma, Follicular Lymphoma, Hodgkin's Lymphoma, Diagnosis and Investigation, Burkitt Lymphoma, Mantle Cell Lymphoma, Peripheral T-cell Lymphoma, Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma

More Cancer Patients Gaining From Immune-Based Treatments

Posted 20 Sep 2016 by Drugs.com

TUESDAY, Sept. 20, 2016 – A leading cancer group says more Americans are benefiting from immunotherapy – a relatively new treatment approach that helps the immune system target and destroy cancer cells. "The promise of immunotherapy for cancer therapy has never been greater, and the opportunity to make significant progress in this critical area is real," said Dr. Nancy Davidson, president of the American Association for Cancer Research (AACR). The AACR issued the news on immunotherapy as part of its 2016 Cancer Progress Report. As the group explained, more types of cancer are being successfully treated with immunotherapy. This treatment involves adding new cancer-fighting cells to the body or adding new elements, such as antibodies and proteins, to help the immune system fight cancer. In August 2015, one class of immunotherapy drugs – called checkpoint inhibitors – was approved for ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Melanoma, Opdivo, Bladder Cancer, Melanoma - Metastatic, Keytruda, Head and Neck Cancer, Hodgkin's Lymphoma, Tecentriq, Nivolumab, Pembrolizumab, Atezolizumab

Scans May Spare Some Hodgkin Lymphoma Patients From Chemo

Posted 23 Jun 2016 by Drugs.com

THURSDAY, June 23, 2016 – A certain type of medical scan can be used to help spare some Hodgkin lymphoma patients from the severe side effects of chemotherapy, a new study suggests. Researchers found that PET imaging can identify patients whose Hodgkin lymphoma will likely respond better to treatment, and therefore require less intensive chemotherapy. "The good news is that the majority of people diagnosed with Hodgkin lymphoma can be cured – in this trial more than 95 percent of patients are alive after three years. But we worry about the long-term side effects from the treatments we use," study leader Peter Johnson, a professor of medical oncology at the University of Southampton in England, said in a university news release. "As we've done in this trial, personalizing treatment based on how well it works is a major development for patients with Hodgkin lymphoma, and sets a new ... Read more

Related support groups: Cancer, Hodgkin's Lymphoma, Diagnosis and Investigation, Body Imaging, Bleomycin, Blenoxane

Opdivo (nivolumab) FDA Approved for the Treatment of Hodgkin Lymphoma

Posted 18 May 2016 by Drugs.com

PRINCETON, N.J., May 17, 2016 --(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the treatment of patients with classical Hodgkin lymphoma (cHL) who have relapsed or progressed after autologous hematopoietic stem cell transplantation (auto-HSCT) and post-transplantation brentuximab vedotin.1 This accelerated approval is based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. This first approval of a PD-1 inhibitor for cHL patients who have relapsed or progressed after auto-HSCT and post-transplantation brentuximab vedotin is based on a combined analysis of data from the Phase 2 CheckMate -205 and the Phase 1 CheckMate -039 trials.1 Based on this analysis (n=95), Opdivo ... Read more

Related support groups: Opdivo, Hodgkin's Lymphoma, Nivolumab

FDA Medwatch Alert: BiCNU (carmustine for injection): FDA Alert - Counterfeit Product Discovered in Some Foreign Countries

Posted 16 May 2016 by Drugs.com

ISSUE: FDA is informing health care professionals that a counterfeit version of the FDA approved cancer drug, BiCNU (carmustine for injection) 100 mg, has been detected in some foreign countries. There is no indication at this time that counterfeit BiCNU has entered the legitimate U.S. drug supply chain and no indication that any U.S. patients have received counterfeit BiCNU. See the FDA Alert for more information, including product photos and affected lot numbers. BACKGROUND: The authentic product is approved to treat different types of brain cancer, multiple myeloma, and lymphoma (Hodgkin’s and non-Hodgkin’s). BiCNU is manufactured by Emcure Pharmaceuticals Ltd. and distributed in the United States by Heritage Pharmaceuticals Inc. BiCNU is available as a vial of BiCNU and dehydrated alcohol co-packaged together. While the NDC on the outer package of the authentic and counterfeit ver ... Read more

Related support groups: Brain Tumor, Multiple Myeloma, Non-Hodgkin's Lymphoma, Glioblastoma Multiforme, Hodgkin's Lymphoma, Malignant Glioma, BiCNU

Young Black, Hispanic Hodgkin Lymphoma Patients Face Worse Outcomes: Study

Posted 3 Feb 2016 by Drugs.com

WEDNESDAY, Feb. 3, 2016 – Hodgkin lymphoma is a form of cancer that starts in white blood cells is often curable. But, poor black and Hispanic young people are less likely to survive the disease than their white peers, a new study shows. "This study identifies vulnerable subgroups of young Hodgkin lymphoma patients at higher risk of dying from their disease, and points to disparities in treatment delivery and follow-up care as likely contributing factors," said study author Theresa Keegan. She is an associate professor in the division of hematology and oncology at the University of California, Davis. "Identifying and reducing barriers to recommended treatment and follow-up care is critical to improving survival for all patients," Keegan said in a university news release. She conducted the research while at the Cancer Prevention Institute of California. For the study, researchers ... Read more

Related support groups: Cancer, Hodgkin's Lymphoma

Lymphoma Survivors May Not Get All Recommended Follow-Up Care

Posted 15 Jan 2016 by Drugs.com

FRIDAY, Jan. 15, 2016 – Some teen and young adult survivors of Hodgkin lymphoma do not receive all the recommended follow-up care, a new study finds. The study included 354 survivors in California who were diagnosed between ages 15 and 39, and followed for an average of six years. Within the first year, 52 percent of the survivors did not receive all recommended care outlined in the National Comprehensive Cancer Network guidelines. But within five years after completing treatment, 96 percent of the survivors had recommended visits (at least one a year) with an oncologist and 70 percent had recommended laboratory testing, according the study authors. The study is scheduled for presentation Friday at an American Society of Clinical Oncology (ASCO) meeting in San Francisco. The findings should be viewed as preliminary until published in a peer-reviewed journal. Hodgkin lymphoma, a cancer ... Read more

Related support groups: Lymphoma, Hodgkin's Lymphoma

Fewer Childhood Cancer Survivors Dying From 'Late' Effects

Posted 13 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 13, 2016 – Fewer childhood cancer survivors are dying years later from lingering effects of the treatment that conquered their cancer, a new study finds. Experts called the report, published in the Jan. 14 issue of the New England Journal of Medicine, "very good news." "The findings substantiate what experts in the field have hoped would be true," said lead researcher Dr. Gregory Armstrong, of St. Jude Children's Research Hospital, in Memphis, Tenn. Survival rates from many childhood cancers are high, but survivors still face what doctors call "late effects" – health problems that develop months to years after the cancer treatment has ended. Among U.S. children who survived cancer back in the 1970s and '80s, 18 percent died within the next 25 years, Armstrong said. Sometimes, the initial cancer comes back. Often though, the health issues are related to the very ... Read more

Related support groups: Cancer, Methotrexate, Fluorouracil, Xeloda, Hydroxyurea, Mercaptopurine, Hydrea, Carboplatin, Cisplatin, Dacogen, Cytoxan, Oxaliplatin, Cyclophosphamide, Temodar, Bendamustine, Capecitabine, Treanda, Gemzar, Gemcitabine, Hodgkin's Lymphoma

Childhood Cancer Tied to Raised Risk for Other Ills in Adult Life

Posted 11 Nov 2015 by Drugs.com

WEDNESDAY, Nov. 11, 2015 – Childhood cancer survivors are at increased risk for diabetes and other autoimmune diseases, a new study suggests. "Cure is no longer a sufficient goal in childhood cancer care," the researchers wrote. "As the vast majority of these patients survive, attention must be paid to their long-term quality of life and health challenges." In the study, the investigators analyzed data from more than 20,000 adults in Denmark, Iceland and Sweden, who had cancer before the age of 20 and survived for at least one year, and compared them to nearly 126,000 adults who did not have childhood cancer. Over an average follow-up of 15 to 19 years, 3.6 percent of childhood cancer survivors were treated in a hospital at least once for an autoimmune disease. That rate is 40 percent higher than among the adults who did not have childhood cancer, according to Dr. Anna Sallfors ... Read more

Related support groups: Diabetes, Type 2, Cancer, Leukemia, Autoimmune Disorders, Brain Tumor, Hodgkin's Lymphoma

Young Cancer Survivors Often Develop New Malignancies

Posted 6 Oct 2015 by Drugs.com

TUESDAY, Oct. 6, 2015 – Teen and young adult cancer survivors are at increased risk for other cancers later in life, a new study reveals. Researchers analyzed U.S. National Cancer Institute data on people who survived cancers before age 40. They had the most common types of cancers in that age group: leukemia, lymphoma, testicular, ovarian, thyroid, breast, soft tissue and bone cancers. "This is a patient demographic that has been largely overlooked," said senior study author Dr. Robert Goldsby, a professor of pediatrics at the University of California, San Francisco Benioff Children's Hospital. Over 30 years, nearly 14 percent of the survivors were diagnosed with another, different type of cancer. On average, the second cancer occurred within 15 years. Compared to people in the general population, patients successfully treated for cancer between ages 15 and 39 were nearly 60 percent ... Read more

Related support groups: Cancer, Breast Cancer, Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Basal Cell Carcinoma, Lymphoma, Melanoma, Skin Cancer, Chronic Lymphocytic Leukemia (CLL), Ovarian Cancer, Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Stomach Cancer, Cutaneous T-cell Lymphoma, Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Soft Tissue Sarcoma, Testicular Cancer, Burkitt Lymphoma

Hodgkin's Lymphoma Survivors Face Higher Long-Term Heart Risks

Posted 27 Apr 2015 by Drugs.com

MONDAY, April 27, 2015 – While treatment for Hodgkin's lymphoma can beat back the once-deadly cancer, it may also render patients vulnerable to heart disease decades later, a new study shows. "Physicians and patients should be aware of the persistently increased risk of cardiovascular diseases throughout life," a team led by Flora van Leeuwen of the Netherlands Cancer Institute in Amsterdam, wrote in the report published online April 27 in JAMA Internal Medicine. According to the American Cancer Society, more than 9,000 people are diagnosed with the blood cancer known as Hodgkin's lymphoma each year. While the disease is now highly treatable, more than 1,100 Americans still die from the illness annually. The disease typically strikes early in life, and is most common in people in their 20s, the society said. Many patients with Hodgkin's lymphoma recover from their illness, and more ... Read more

Related support groups: Heart Disease, Hodgkin's Lymphoma

New Drug May Help Keep Hodgkin Lymphoma at Bay

Posted 18 Mar 2015 by Drugs.com

WEDNESDAY, March 18, 2015 – An FDA-approved drug doubled the amount of time that patients with Hodgkins lymphoma survived without any progression in their disease, a new study shows. All of the patients also received stem cell therapy along with the drug, called brentuximab vedotin. While the results are encouraging, doctors may never know if the drug is actually lengthening patients' lives, said Dr. Owen O'Connor, director of the Center for Lymphoid Malignancies at Columbia University Medical Center in New York City. That's because brentuximab is fast becoming standard care for all patients with Hodgkin lymphoma who've relapsed after stem cell transplant, he said. So, a trial comparing the survival of patients who got the drug against those who did not might never be feasible, due to ethical concerns. O'Connor was not involved in the trial, which was led by Dr. Craig Moskowitz, ... Read more

Related support groups: Hodgkin's Lymphoma, Adcetris, Brentuximab

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Lymphoma

Related Drug Support Groups

methotrexate, Opdivo, Keytruda, Cytoxan, cyclophosphamide, doxorubicin, Adriamycin, Leukeran, vincristine, view more... nivolumab, vinblastine, etoposide, pembrolizumab, Velban, procarbazine, Adcetris, dacarbazine, Oncovin, chlorambucil, DTIC-Dome, Blenoxane, brentuximab, lomustine, bleomycin, BiCNU, Adriamycin PFS, Bleo 15k, Adriamycin RDF, Gleostine, carmustine, Cytoxan Lyophilized, Etopophos, VePesid, Gliadel, Toposar, CeeNU, Vincasar PFS, Matulane, Neosar